Radiation and CSPG4-specifc CAR T cell based combinatorial therapy for the in vivo treatment of TNBC
Radiation and CSPG4-specifc CAR T cell based combinatorial therapy for the in vivo treatment of TNBC
批准号:
10447683
负责人:
Dan Gabriel Duda
金额:
$8.37万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-07-08 至 2024-06-30
关键词:
AdenosineAntigensApoptosisApoptoticBiological ModelsBreast Cancer CellBreast Cancer PatientCAR T cell therapyCell CommunicationCellsCellular immunotherapyChemoresistanceChondroitin Sulfate AChondroitin Sulfate ProteoglycanClinicalClinical TrialsCombination immunotherapyDiseaseDoseEffector CellEquilibriumGenerationsGrowthHeterogeneityHistocompatibility Antigens Class IHumanHypoxiaImmuneImmunodeficient MouseImmunotherapeutic agentIn VitroLeadLesionLiteratureMalignant NeoplasmsMediatingMembraneMolecularMonoclonal AntibodiesMorbidity - disease rateMusNormal CellNormal tissue morphologyPatientsPericytesPlayRadiationRadiation exposureRadiation therapyRecurrenceRoleSolid NeoplasmSpecificityT cell therapyT-LymphocyteTestingTherapeuticTreatment EfficacyTumor AntigensTumor-infiltrating immune cellsUp-RegulationXenograft procedureanti-PD-1anti-PD-L1basecancer cellchimeric antigen receptorchimeric antigen receptor T cellsclinical applicationclinically relevantcombinatorialcytotoxicdesigneffective therapyengineered T cellsexhaustiongenetically modified cellsin vivomortalitymouse modelneoplastic cellnew therapeutic targetnovelprogrammed cell death ligand 1programmed cell death protein 1radiation resistancerational designresponsetargeted treatmenttraffickingtreatment strategytriple-negative invasive breast carcinomatumortumor microenvironment
中文摘要
项目摘要/摘要
由于化疗和化疗,三阴性乳腺癌(TNBC)缺乏有效的治疗选择
新型靶向治疗的抗辐射和低疗效。因为这些令人失望的事情
临床结果,我们已经评估了CSPG4特异性嵌合体的潜在临床治疗应用
以抗原受体(CAR)T细胞为基础的治疗TNBCCSPG4已被选为目标,
由于这种肿瘤抗原(TA)在大约70%的原发和转移性TNBC肿瘤中表达。此外,
CSPG4在TNBC肿瘤起始细胞(CICs)上表达,CICs被认为在转移中起作用
传播和疾病复发是患者发病率和死亡率的两大原因。最后,CSPG4是
在正常细胞上检测不到,但在肿瘤微环境(TME)中激活的周细胞除外。
我们已经证明CSPG4 CAR T细胞在清除分化的TNBC细胞和TNBC CIC方面是有效的
在体外,但不能完全根除在免疫缺陷小鼠身上移植的TNBC肿瘤。这一差异
可能反映了TME对CSPG4特异性CAR T细胞-TNBC细胞相互作用的负面影响
T细胞在肿瘤中的浸润性。为了消除这些阻碍CAR T细胞疗法成功应用的障碍,
我们将把CSPG4特异的CAR T细胞与辐射结合起来。这种组合策略是基于我们的
初步结果,结合文献中的信息表明,肿瘤辐射可以
用TNBC细胞增强CSPG4特异性CAR T细胞的抗肿瘤活性。这种影响似乎是
由多种机制介导,其中,显著上调TNBC细胞上CSPG4的表达,
参与细胞凋亡的分子的调节和增加T细胞的渗透和持久性似乎是
牵涉其中。这项建议的具体目的是:1)评估肿瘤放射是否增强了
CSPG4特异性CAR T细胞清除NRG小鼠原位移植的人TNBC细胞和II)评估
CSPG4特异性CAR T细胞与CSPG4联合应用增强能力的分子机制(S)
辐射根除NRG小鼠原位移植的人TNBC细胞。这些结果将有助于
优化组合放疗和CSPG4特异性CAR T细胞治疗TNBC的策略。
英文摘要
Project Summary/Abstract
Effective treatment options for triple negative breast cancer (TNBC) are lacking due to chemotherapy and
radiation resistance and low therapeutic efficacy of novel targeted therapies. Because of these disappointing
clinical results, we have assessed the potential therapeutic clinical application of a CSPG4-specific chimeric
antigen receptor (CAR) T cell-based therapy for the treatment of TNBC. CSPG4 has been selected as the target,
since this tumor antigen (TA) is expressed in about 70% of primary and metastatic TNBC tumors. Furthermore,
CSPG4 is expressed on TNBC cancer initiating cells (CICs), which are believed to play a role in metastatic
spreading and disease recurrence, the two major causes of patients' morbidity and mortality. Lastly, CSPG4 is
not detectable on normal cells with the exception of activated pericytes in the tumor microenvironment (TME).
We have shown that CSPG4 CAR T cells are effective in eliminating differentiated TNBC cells and TNBC CICs
in vitro, but are not able to completely eradicate TNBC tumors grafted in immunodeficient mice. This discrepancy
may reflect the negative impact of TME on CSPG4-specific CAR T cell-TNBC cell interactions as well as poor
T cell infiltration of the tumor. To counteract these obstacles to the successful application of CAR T cell therapy,
we will combine CSPG4-specific CAR T cells with radiation. This combinatorial strategy is based on our
preliminary results, which in combination with the information in the literature show that tumor radiation can
enhance the antitumor activity of CSPG4-specific CAR T cells with TNBC cells. This effect appears to be
mediated by multiple mechanisms, of which, a significant upregulation of CSPG4 expression on TNBC cells,
modulation of molecules involved in cell apoptosis and increased T cell infiltration and persistence seem to be
involved. The specific aims of this proposal are to i) evaluate whether tumor radiation enhances the ability of
CSPG4-specific CAR T cells to eradicate human TNBC cells orthotopically grafted in NRG mice and ii) assess
the molecular mechanism(s) underlying the increased ability of CSPG4-specific CAR T cells in combination with
radiation to eradicate human TNBC cells orthotopically grafted in NRG mice. These results will contribute to
optimize a combinatorial radiation and CSPG4-specific CAR T cell-based strategy for the treatment of TNBC.
期刊论文(9)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1002/jha2.408
发表时间:
2022-05
期刊:
EJHaem
影响因子:
--
作者:
[How, Joan, Ren, Siyang, Lombardi-Story, Jennifer, Bergeron, Meghan, Foster, Julia, Amrein, Phillip C., Brunner, Andrew M., Fathi, Amir T., Hock, Hanno, Khachatryan, Anna, Kikuchi, Hiroto, Ng, Mei Rosa, Moran, Jenna, Narayan, Rupa, Neuberg, Donna, Ramos, Aura, Som, Tina, Vartanian, Meghan, Chen, Yi-Bin, Duda, Dan G., Hobbs, Gabriela S.]
通讯作者:
Hobbs, Gabriela S.
DOI:
10.3390/cancers13194919
发表时间:
2021-09-30
期刊:
Cancers
影响因子:
5.2
作者:
[Klein S, Duda DG]
通讯作者:
Duda DG
DOI:
10.3390/cancers13225725
发表时间:
2021-11-16
期刊:
Cancers
影响因子:
5.2
作者:
[Gkika E, Adebahr S, Brenner A, Schimek-Jasch T, Radicioni G, Exner JP, Rühle A, Spohn SKB, Popp I, Zamboglou C, Sprave T, Firat E, Niedermann G, Nicolay NH, Nestle U, Grosu AL, Duda DG]
通讯作者:
Duda DG
Refining genetic and molecular classifications to facilitate breakthrough treatments in intrahepatic cholangiocarcinoma: are we there yet?
完善遗传和分子分类以促进肝内胆管癌的突破性治疗:我们做到了吗?
DOI:
10.1136/gutjnl-2022-327782
发表时间:
2023
期刊:
Gut
影响因子:
24.5
作者:
[Morita,Satoru, Duda,DanG]
通讯作者:
Duda,DanG
DOI:
10.3390/ijms23041926
发表时间:
2022-02-09
期刊:
International journal of molecular sciences
影响因子:
5.6
作者:
[Hauth F, Roberts HJ, Hong TS, Duda DG]
通讯作者:
Duda DG
共 6 条
Defining Optimal Radiotherapy Dose and Fractionation in Combination with Preoperative Immuno-Chemotherapy in Early-Stage Triple Negative Breast Cancer
-
批准号:10512391
-
项目类别:
-
资助金额:$35.55万
-
财政年份:2023
-
负责人:Dan Gabriel Duda
-
依托单位:
Radiation and CSPG4-specifc CAR T cell based combinatorial therapy for the in vivo treatment of TNBC
-
批准号:10290575
-
项目类别:
-
资助金额:$8.37万
-
财政年份:2021
-
负责人:Dan Gabriel Duda
-
依托单位:
Vascularized tumor explants for drug testing
-
批准号:10317398
-
项目类别:
-
资助金额:$37.81万
-
财政年份:2021
-
负责人:Dan Gabriel Duda
-
依托单位:
Multiplexed time domain fluorescence tomography of tumor biomarkers during immunotherapy
-
批准号:10372211
-
项目类别:
-
资助金额:$44.33万
-
财政年份:2021
-
负责人:Dan Gabriel Duda
-
依托单位:
Vascularized tumor explants for drug testing
-
批准号:10424580
-
项目类别:
-
资助金额:$37.05万
-
财政年份:2021
-
负责人:Dan Gabriel Duda
-
依托单位:
Multiplexed time domain fluorescence tomography of tumor biomarkers during immunotherapy
-
批准号:10983625
-
项目类别:
-
资助金额:$20.5万
-
财政年份:2021
-
负责人:Dan Gabriel Duda
-
依托单位:
Vascularized tumor explants for drug testing
-
批准号:10642870
-
项目类别:
-
资助金额:$37.05万
-
财政年份:2021
-
负责人:Dan Gabriel Duda
-
依托单位:
Multiplexed time domain fluorescence tomography of tumor biomarkers during immunotherapy
-
批准号:10600866
-
项目类别:
-
资助金额:$24.07万
-
财政年份:2021
-
负责人:Dan Gabriel Duda
-
依托单位:
Role of SDF1a pathway in prostate cancer relapse and metastasis post-radiotherapy
-
批准号:8493794
-
项目类别:
-
资助金额:$30.54万
-
财政年份:2011
-
负责人:Dan Gabriel Duda
-
依托单位:
Role of SDF1a pathway in prostate cancer relapse and metastasis post-radiotherapy
-
批准号:8678707
-
项目类别:
-
资助金额:$31.52万
-
财政年份:2011
-
负责人:Dan Gabriel Duda
-
依托单位:
Role of SDF1a pathway in prostate cancer relapse and metastasis post-radiotherapy
-
批准号:8322620
-
项目类别:
-
资助金额:$32.49万
-
财政年份:2011
-
负责人:Dan Gabriel Duda
-
依托单位:
Role of SDF1a pathway in prostate cancer relapse and metastasis post-radiotherapy
-
批准号:8193323
-
项目类别:
-
资助金额:$31.69万
-
财政年份:2011
-
负责人:Dan Gabriel Duda
-
依托单位:
Role of SDF1a pathway in prostate cancer relapse and metastasis post-radiotherapy
-
批准号:8856163
-
项目类别:
-
资助金额:$32.49万
-
财政年份:2011
-
负责人:Dan Gabriel Duda
-
依托单位:
Visualizing Immune Responses in vivo: a systems biology approach
-
批准号:7738611
-
项目类别:
-
资助金额:$22.55万
-
财政年份:2009
-
负责人:Dan Gabriel Duda
-
依托单位:
Overcoming Evasion from Sorafenib in HCC
-
批准号:8657993
-
项目类别:
-
资助金额:$24.62万
-
财政年份:--
-
负责人:Dan Gabriel Duda
-
依托单位:
Overcoming Evasion from Sorafenib in HCC
-
批准号:8299760
-
项目类别:
-
资助金额:$25.53万
-
财政年份:--
-
负责人:Dan Gabriel Duda
-
依托单位:
Overcoming Evasion from Sorafenib in HCC
-
批准号:8876591
-
项目类别:
-
资助金额:$25.47万
-
财政年份:--
-
负责人:Dan Gabriel Duda
-
依托单位:
Overcoming Evasion from Sorafenib in HCC
-
批准号:8463133
-
项目类别:
-
资助金额:$23.94万
-
财政年份:--
-
负责人:Dan Gabriel Duda
-
依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
-
批准号:2022J011295
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:王亚伟
-
依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
-
批准号:30801055
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:王丽梅
-
依托单位: